Picture [iito] No Tracking 650x80px
Document › Details

Oxford Biomedica plc. (3/7/16). "Press Release: Oxford BioMedica Announces Expanded Collaboration and Licence with Immune Design". Oxford.

Organisations Organisation Oxford Biomedica plc (LSE: OXB)
  Group Oxford Biomedica (Group)
  Organisation 2 Immune Design Corporation (Nasdaq: IMDZ)
Products Product LentiVector® technology
  Product 2 cancer immunotherapy (immuno-oncology, I-O)
Index terms Index term Immune Design–Oxford BioMedica: lentiviral vector technology, 201603– collab expansion + non-excl IP license €na
  Index term 2 Immune Design–Oxford BioMedica: lentiviral vector technology, 2012– collab process developm incl analytic assays
Persons Person Dawson, John (Oxford BioMedica 200810– CEO before Cephalon Europe)
  Person 2 Elliott, Mary-Jane (Consilium SC 201307– Managing Partner + Co-founder before M:Communications)

Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: OXB), a leading gene and cell therapy group, today announced a new and expanded collaboration with Immune Design Corp. (“Immune Design”), a clinical-stage immunotherapy company focused in oncology, as well as a non-exclusive, royalty-bearing, intellectual property licence to Immune Design.

The licence involves the use of lentiviral vector-based products for the in vivo treatment or prevention of cancer. The collaboration builds on Immune Design’s earlier process development collaboration with the Group, signed in 2012, which covered the development of analytic assays. Financial and other terms have not been disclosed.

John Dawson, Chief Executive Officer of Oxford BioMedica, commented: “We are delighted to sign an IP licence and an expanded collaboration agreement with Immune Design. Oxford BioMedica has world-leading capabilities in lentiviral vector process development and manufacture and these agreements with Immune Design are further evidence of our attractiveness as a partner to other companies and academic institutions working with lentiviral vector based products. I expect that during 2016 we will be able to make further announcements of similar agreements with other parties”


Notes to editors:

Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a leading gene and cell therapy Group with an unrivalled portfolio of gene therapy products in development and a platform of exclusive and pioneering technologies with which it designs, develops and manufactures unique gene-based medicines for some of world’s largest pharmaceutical companies. Leveraging its proprietary LentiVector® IP and gene delivery system technology platform and unique tumour antigen (5T4), Oxford BioMedica is advancing its pipeline of six gene therapy products addressing diseases for which there are currently no treatments or that are inadequately treated today, including ocular and central nervous system disorders. OXB Solutions, the Group's industry-leading manufacturing and development business, provides services to collaborators and partners working in gene and cell therapy, including Novartis and Immune Design Corp. In addition, the Group has licenced products and IP to Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen, Emergent BioSolutions and ImaginAb. Further information is available at

For further information please contact:

Oxford BioMedica plc
John Dawson, Chief Executive Officer
Tim Watts, Chief Financial Officer
Tel: +44 (0)1865 783 000

Consilium Strategic Communications - Media Enquiries
Mary-Jane Elliott
Tel: +44 (0)20 7920 2345

Record changed: 2020-06-08


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for Oxford Biomedica (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

» top